Sartorius launched a rationally designed CHO host cell line that the company reported delivers up to two‑fold higher expression titers and up to three‑fold productivity gains across multiple therapeutic formats. Sartorius said the host maintained product quality and clone stability across long generations, supporting manufacturing consistency for mAbs, Fc-fusions and bispecifics. Complementing that announcement, industry commentary on genome editing for biomanufacturing highlighted transposase and targeted engineering approaches to accelerate CHO optimization and complex biologic production. Together these developments signal continued investment in host-cell engineering to reduce COGS and speed cell-line development.